Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.
Giovanni FucàRomain CohenSara LonardiKohei ShitaraMaria Elena ElezMarwan FakihJoseph ChaoSamuel J KlempnerMatthew EmmettPriya JayachandranFrancesca BergamoMarc Díez GarcíaGiacomo MazzoliLeonardo ProvenzanoRaphael ColleMagali SvrcekMargherita AmbrosiniGiovanni RandonAakash Tushar ShahMassimiliano SalatiElisabetta FenocchioLisa SalvatoreKeigo ChidaAkihito KawazoeVeronica ConcaGiuseppe CuriglianoFrancesca CortiChiara CremoliniMichael OvermanThierry AndréFilippo PietrantonioPublished in: Journal for immunotherapy of cancer (2022)
Patients with dMMR/MSI-H gastrointestinal cancers with peritoneal metastases and ascites should be considered as a peculiar subgroup with highly unfavorable outcomes to current ICI-based therapies. Novel strategies to target the immune-suppressive niche in malignant effusions should be investigated, as well as next-generation ICIs or intraperitoneal approaches.